Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer

被引:28
|
作者
Hondelink, Liesbeth M. [1 ]
Huyuk, Melek [2 ]
Postmus, Pieter E. [2 ]
Smit, Vincent T. H. B. M. [1 ]
Blom, Sami [3 ]
von der Thusen, Jan H. [4 ]
Cohen, Danielle [1 ]
机构
[1] Leiden Univ, Dept Pathol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands
[3] Aiforia Technol Oy, Helsinki, Finland
[4] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
关键词
artificial intelligence; computational pathology; immunotherapy; non-small cell lung cancer; programmed death-ligand 1; PD-L1; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB;
D O I
10.1111/his.14571
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims Immunohistochemical programmed death-ligand 1 (PD-L1) staining to predict responsiveness to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) has several drawbacks: a robust gold standard is lacking, and there is substantial interobserver and intraobserver variance, with up to 20% discordance around cutoff points. The aim of this study was to develop a new deep learning-based PD-L1 tumour proportion score (TPS) algorithm, trained and validated on a routine diagnostic dataset of digitised PD-L1 (22C3, laboratory-developed test)-stained samples. Methods and results We designed a fully supervised deep learning algorithm for whole-slide PD-L1 assessment, consisting of four sequential convolutional neural networks (CNNs), using aiforia create software. We included 199 whole slide images (WSIs) of 'routine diagnostic' histology samples from stage IV NSCLC patients, and trained the algorithm by using a training set of 60 representative cases. We validated the algorithm by comparing the algorithm TPS with the reference score in a held-out validation set. The algorithm had similar concordance with the reference score (79%) as the pathologists had with one another (75%). The intraclass coefficient was 0.96 and Cohen's kappa coefficient was 0.69 for the algorithm. Around the 1% and 50% cutoff points, concordance was also similar between pathologists and the algorithm. Conclusions We designed a new, deep learning-based PD-L1 TPS algorithm that is similarly able to assess PD-L1 expression in daily routine diagnostic cases as pathologists. Successful validation on routine diagnostic WSIs and detailed visual feedback show that this algorithm meets the requirements for functioning as a 'scoring assistant'.
引用
收藏
页码:635 / 647
页数:13
相关论文
共 50 条
  • [21] CLINICAL VALIDATION OF AN IMAGE ANALYSIS ASSAY FOR DETERMINING PROGRAMMED DEATH-LIGAND 1 (22C3) IN NON-SMALL CELL LUNG CANCER
    Gianani, Roberto
    Paces, Will
    Ergon, Elliott
    Shotts, Kristin
    Adisetiyo, Vitria
    Caldwell, Charles
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A23 - A23
  • [22] Programmed Death-ligand 1 Expression Analysis for Non-small Cell Lung Cancer in Tissues Sampled Using Different Methods
    Urer, Halide Nur
    Gunluoglu, Mehmet Zeki
    Cansever, Levent
    Bedirhan, Mehmet Ali
    HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2020, 58 (02): : 135 - 141
  • [23] Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer
    Dong, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S923 - S923
  • [24] Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
    Kim, Hyojin
    Kwon, Hyun Jung
    Park, Soo Young
    Park, Youngmi
    Park, Eunhyang
    Chung, Jin-Haeng
    PLOS ONE, 2018, 13 (06):
  • [25] Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer
    Villaruz, Liza C.
    Blumenschein Jr, George R.
    Otterson, Gregory A.
    Leal, Ticiana A.
    CANCER, 2023, 129 (09) : 1319 - 1350
  • [26] Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?
    Bravaccini, Sara
    Bronte, Giuseppe
    CANCER CYTOPATHOLOGY, 2018, 126 (09) : 817 - 818
  • [27] MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer
    Grenda, Anna
    Nicos, Marcin
    Szczyrek, Michal
    Krawczyk, Pawel
    Kucharczyk, Tomasz
    Jarosz, Bozena
    Pankowski, Juliusz
    Sawicki, Marek
    Szumilo, Justyna
    Bukala, Paulina
    Milanowski, Janusz
    ONCOLOGY LETTERS, 2019, 17 (06) : 5193 - 5200
  • [28] Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer
    Chen, Jingyi
    Chen, Yusong
    Feng, Fenglan
    Chen, Cheng
    Zeng, Haikang
    Wen, Shuai
    Xu, Xin
    He, Jianxing
    Li, Jin
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6711 - +
  • [29] CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer
    Xu, Ting
    Liu, Xiaowen
    Chen, Yaxi
    Wang, Shuxing
    Jiang, Changsi
    Gong, Jingshan
    BMC MEDICAL IMAGING, 2024, 24 (01):
  • [30] Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status
    Holmes, Mikaela
    Mahar, Annabelle
    Lum, Trina
    Kao, Steven
    Cooper, Wendy Anne
    JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (02) : 123 - 128